- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02029859
Sleep Apnea, Obesity and Pregnancy (GOS)
Main objective:
Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .
Secondary objectives :
- Identify risk factors for OSA during pregnancy (age, parity, high blood pressure, snoring , weight, neck circumference, scores on symptoms of sleep apnea, ... ) .
- Compare perinatal morbidity among obese patients with OSA in late pregnancy with case-controls.
- Evaluate the evolution of a moderate or severe OSA 6 months after pregnancy.
Material and methods
Characteristics of the study:
- Interventional biomedical research
- Prospective Multicenter nonrandomized study
Flow chart
- Patients will be included between 30 and 36 weeks of amenorrhea (WA) .
- Will rated from inclusion: age, parity, weight, height, BMI in early pregnancy, neck circumferrence, treated high blood pressure.
- As recommended in France, the main test results during the pregnancy follow-up will be recorded.
- At the inclusion visit will be conducted a Berlin Questionnaire and Epworth Score.
- Screening for OSA by nocturnal polysomnography will be performed between 30 and 36WA. This screening can be performed as an outpatient.
- In case of proven OSA patients will be offered an appropriate care by today's standards.
- Whatever the outcome of pregnancy, a second polysomnography will be performed 6 months after childbirth in case of OSA during pregnancy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49000
- Angers University Hospital
-
Caen, France, 14000
- Caen University hospital
-
Le Havre, France, 76290
- Le Havre Hospital
-
Rouen, France, 76000
- Rouen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI >35
- Pregnancy after 30 Weeks of amenorhea
- Age > 18
- Signed consentment
- Nationnal Health Program affiliation
Exclusion Criteria:
- Twin or more pregnancy
- Imprecise term
- Artificial insemination with donor gametes
- Proved thrombophilia
- chronic renal failure
- Previously treated (with CPAP) obstructive sleep apnea syndrom
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prevalence of obstructive sleep apnea syndrome
Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients . Polygraphic examination between 30 and 36 weeks of amenorhea |
Polygraphic examination between 30 and 36 weeks of amenorhea
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep apnea syndrom prevalence
Time Frame: 6 weeks
|
Polygraphic examination for all subjects will determine the sleep apnea syndrom prevalence during late pregnancy (after 30 weeks of amenorhea) for severe obese women (BMI>35).
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Loic Marpeau, PHD, Rouen University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009/070/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.